Stockscreener 앱 받기
3.27
0.46%
-0.01
Solid Biosciences Inc 주식(SLDB)의 최신 뉴스
Cantor Fitzgerald Estimates SLDB FY2025 Earnings - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of “Buy” from Analysts - Defense World
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart - Seeking Alpha
Solid Biosciences gets FDA Fast Track for FA gene therapy - Investing.com India
Solid Biosciences' Ataxia Treatment Receives FDA Fast-Track Designation - MarketWatch
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia - Yahoo Finance
Barclays PLC Acquires 50,582 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia - MSN
Solid Biosciences Initiates Clinical Trial For Duchenne Therapy SGT-003 - RTTNews
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines - The Manila Times
Solid Biosciences Advances Gene Therapy Pipeline, Reports Strong $148.9M Cash Position - StockTitan
Solid Bio draws buy from Truist on valuation and catalysts - MSN
Jane Street Group LLC Has $145,000 Stock Holdings in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences CFO Kevin Tan sells $15,849 in company stock By Investing.com - Investing.com Australia
Solid Biosciences CFO Kevin Tan sells $15,849 in company stock - Investing.com India
Kevin Tan Sells 4,073 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) Stock - MarketBeat
Solid Biosciences' SWOT analysis: gene therapy firm's stock poised for growth - Investing.com
Q1 EPS Forecast for Solid Biosciences Reduced by Analyst - Defense World
HC Wainwright Reiterates “Buy” Rating for Solid Biosciences (NASDAQ:SLDB) - Defense World
Solid Biosciences stock hits 52-week low at $3.78 By Investing.com - Investing.com Australia
Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from HC Wainwright - MarketBeat
Solid Biosciences stock hits 52-week low at $3.78 - Investing.com
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development (CORRECTED) - Benzinga
Solid Bio stock draws buy from Truist (SLDB:NASDAQ) - Seeking Alpha
Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from Analysts at Truist Financial - MarketBeat
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Truist Securities Initiates Coverage of Solid Biosciences (SLDB) with Buy Recommendation - MSN
FDA Nod Sends Solid Biosciences (SLDB) Soaring After-Hours - Stocks Telegraph
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia - Yahoo Finance
FDA clears Solid Biosciences' gene therapy IND for FA By Investing.com - Investing.com South Africa
Solid Biosciences director Ilan Ganot sells $4,551 in stock By Investing.com - Investing.com Canada
Solid Biosciences stock jumps 11% post-market on FDA update - MSN
FDA clears Solid Biosciences' gene therapy IND for FA - Investing.com India
Solid Biosciences director Ilan Ganot sells $4,551 in stock - Investing.com
Solid Biosciences Gains FDA Clearance for New Drug Application - MarketWatch
Solid Biosciences' Revolutionary Dual-Route Gene Therapy for Friedreich's Ataxia Gains FDA Clearance - StockTitan
Solid Biosciences Inc. (NASDAQ:SLDB) Shares Sold by Geode Capital Management LLC - Defense World
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences Awards Stock Incentives to New Key Employee Under 2024 Plan - StockTitan
Solid Biosciences stock hits 52-week low at $3.9 amid challenges - Investing.com Australia
Solid Biosciences stock hits 52-week low at $3.9 amid challenges By Investing.com - Investing.com South Africa
State Street Corp Grows Stock Position in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Analysts Set Solid Biosciences Inc. (NASDAQ:SLDB) Price Target at $15.22 - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of “Buy” by Analysts - Defense World
SLDBSolid Biosciences Inc. Latest Stock News & Market Updates - StockTitan
Solid Biosciences Added to the Nasdaq Biotechnology Index - GlobeNewswire
1.88%
5.20%
자본화:
|
볼륨(24시간):